Sign Up to like & get
recommendations!
1
Published in 2022 at "Biotechnology Journal"
DOI: 10.1002/biot.202100629
Abstract: Difucosyllactose (Di‐FL) has strong antimicrobial activity against various pathogens, including group B Streptococcus, identified as the leading cause of neonatal sepsis. In this study, we sought to develop Escherichia coli as a microbial cell factory…
read more here.
Keywords:
fucosyllactose difucosyllactose;
difucosyllactose engineered;
escherichia coli;
simultaneous production ... See more keywords